CLL Society Webinar
Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise? Description: Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these […]